NCT00368251 - Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Unverricht-Lundborg Disease

Interventions

OTHER

Placebo

"* Pharmaceutical Form: Tablet~* Concentration: 2.5 mg, 25 mg and 50 mg~* Route of Administration: Oral use"

DRUG

BRV 2.5 mg

"* Pharmaceutical Form: Tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use"

DRUG

BRV 25 mg

"* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use"

DRUG

BRV 50 mg

"* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"

Trial Locations (18)

135, San Francisco

133, Gainesville

132, New York

131, Charlottesville

151, Vancouver

150, Montreal

152, Québec

100, Helsinki

122, Bron

121, Lille

120, Paris

170, Tel Aviv

141, Moscow

142, Saint Petersburg

143, Samara

161, Belgrade

162, Belgrade

180, Manouba